Corsair Signs Strategic Partnership with Kera Energy for Global Distribution of Pyrolysis Oil
New partnership expands global access to Corsair's recycled plastic oil across Europe, Asia, and the Americas.
AMSTERDAM, NETHERLANDS / ACCESS Newswire Plastic waste recycling company Corsair Group International Holding BV (CORSAIR) is proud to announce a new strategic partnership with KERA Energy AG, a Swiss-based leader in sustainable industrial value chains. Under the agreement, CORSAIR will supply advanced pyrolysis oil to KERA Energy, which will distribute the Plastic Pyrolysis Oil (PPO) across key markets in Europe, Asia, and the Americas.
This collaboration marks another important step in CORSAIR's mission to scale up sustainable advanced recycling of plastic waste. The agreement with KERA Energy signals growing international demand for CORSAIR's high-quality pyrolysis oil derived from everyday household plastic waste.
'We are very pleased to partner with KERA Energy, a company that shares our vision of a cleaner, circular economy,' said Jussi Veikko Saloranta, CEO of CORSAIR. 'KERA's extensive expertise and market access will allow us to accelerate our environmental impact and expand our reach globally.'
Founded in 1999 and headquartered in Zug, Switzerland, KERA Energy AG specializes in the optimization of supply chains and the commercialization of sustainable raw materials such as plastic pyrolysis oil (PPO) and tire pyrolysis oil (TPO). With a processing capacity of up to 300,000 tons per year and compliance with ISCC+ and REACH regulations, KERA is at the forefront of enabling circular and bio-based feedstock solutions for the chemical and refining industries.
'We are proud to partner with CORSAIR as we jointly work to eliminate plastic waste from our environment,' said Shane Perl, CEO of KERA Energy.
By utilizing CORSAIR's pyrolysis oil, produced from mixed plastic household waste at facilities in Thailand, Finland and its future facilities, KERA will support the production of new, sustainable plastics and chemicals, reducing dependency on fossil-based virgin feedstocks, diverting plastic waste destined for landfill or incineration and contributing to a closed-loop system for plastic materials.
'We work with pyrolysis companies from concept to technical development and on to commercially optimizing their circular and bio-based oil products.'
Simon Housecraft, Head of Sustainable Materials at KERA, states: 'We are committed to building a bridge between environmental goals and industrial performance, and this partnership with CORSAIR embodies that commitment. We believe CORSAIR will remain one of the global leaders within this market sector with ambitious but, realistic expansion plans. As a partnership, we believe we can successfully deliver circularity to our market sector'
With this new alliance, CORSAIR strengthens its role as the fastest growing company in advanced plastic recycling and takes another key step toward a world where waste is transformed into valuable resources for the future.
For more information, please visit
www.corsairgroup.com
Contact Info
mail: info@corsairnow.com
phone: +66 957 613 702
SOURCE: Corsair group
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Cresilon Announces International Distribution Agreement for VETIGEL with McCarthy Vet
Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply company NEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy Vet, a full-service veterinary marketing, supply and distribution company exclusively serving veterinarians in the Canadian animal health industry. VETIGEL, a revolutionary plant-based hemostatic gel that instantly stops and controls bleeding, is now available for veterinarian surgeons across Canada through McCarthy Vet. The agreement with McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, is Cresilon's first veterinary distribution partnership in Canada. "Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes." Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective hemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based hemostatic gel for veterinary surgeons has been used in more than 60,000 surgical procedures worldwide. As McCarthy Vet expands its portfolio through a new partnership with VETIGEL, the company remains focused on delivering the solutions today's veterinary professionals need most. This collaboration reflects its ongoing promise to bring innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients. As a flowable hemostatic gel, VETIGEL offers veterinary surgeons a safe and efficient way to control bleeding across a wide range of surgical procedures and wound geometries. The veterinary hemostatic agent is biocompatible, non-animal derived, and made with an innovative blend of plant polymers that form an instant mechanical barrier to stop bleeding on contact. Once the bleeding is controlled, VETIGEL can be easily removed without disturbing the underlying clot or left in the body to resorb. VETIGEL is supplied in a pre-filled syringe, easy-to-use, and requires no preparation or special storage conditions. For more information about VETIGEL, visit For more information about McCarthy Vet, visit About CresilonCresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company's current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit About McCarthy VetMcCarthy Veterinary Supplies has proudly served Canadian Veterinarians for over 60 years. McCarthy is committed to bringing clinics the most innovative products, expertise, and service to improve the health of animals, and thereby improve the lives of those who care for them. McCarthy is based in Alberta, Canada, with reps exclusively serving veterinarians in every province from coast to coast. View original content to download multimedia: SOURCE Cresilon
Yahoo
30 minutes ago
- Yahoo
Bracco Imaging and Subtle Medical obtain CE mark for AI-powered MRI software
Italy-based Bracco Imaging and Subtle Medical have obtained an EU CE mark for AiMIFY, a jointly developed software designed to enhance the imaging of contrast MRI brain scans using artificial intelligence (AI). Developed through the application of Bracco's imaging and Subtle's software, clinical evidence has demonstrated that AiMIFY provides contrast enhancement for MRI brain scans up to twice the level typically achieved with a labelled dose of gadolinium-based contrast agents (GBCAs). Consequently, AiMIFY enhances the visualisation of small and poorly enhanced lesions that are critical to the early detection of certain conditions. US-based Subtle Medical's chief product officer, Ajit Shankaranarayanan, points out that in achieving imaging enhancements in contrast MRI scans, whereby a contrast agent is administered to a patient before an MRI is undertaken, the software requires no adjustments to these standard practices. According to the companies, validation data for AiMIFY, which was granted software as a medical device (SaMD) clearance from the US Food and Drug Administration (FDA) in October 2024, has demonstrated the technology's efficacy across diverse patient demographics, pathologies, lesion sizes, scanner vendors, MRI sequences, and acquisition orientations. Radiology platform leader at Bracco Imaging, Sascha Daeuber commented: 'With the CE Mark for AiMIFY, we're taking the next step in our shared mission to deliver innovative, AI-powered solutions that enhance diagnostic precision and support radiologists and patients worldwide." Bracco and Subtle Medical stated that they will now initiate commercialisation activities for AiMIFY in select European markets, with a phased commercial rollout expected between late 2025 and early 2026. According to a 2023 report by GlobalData, the use of AI across healthcare is burgeoning, with the market forecast to reach a valuation of around $19bn by 2027. Radiology has emerged as one of the most common areas in which AI is being applied – as a means to drive efficiencies and alleviate clinician burnout. In a recent report by KPMG on AI's impact on healthcare, 86% of healthcare professionals expressed their belief that AI adoption would give their organisation a competitive edge over those who did not. "Bracco Imaging and Subtle Medical obtain CE mark for AI-powered MRI software" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
31 minutes ago
- Yahoo
Commerce Bancshares to buy Florida peer FineMark in $585 million deal
(Reuters) -U.S. regional bank Commerce Bancshares has agreed to acquire rival FineMark Holdings in an all-stock deal valued at $585 million, the companies said on Monday. Consolidation among U.S. banks is expected to heighten as rising technology and compliance costs push lenders to scale via mergers and acquisitions. A lighter regulatory touch under the Trump administration is also fueling prospects of bigger deals. Shareholders will receive 0.69 shares of Commerce for each share of FineMark they hold. As of the market close on Friday, the terms represent a 54.7% premium for FineMark shareholders, according to Reuters calculations. Founded in 2007, Florida-based FineMark offers wide-ranging banking and non-banking services to clients through 13 offices in Florida, Arizona and South Carolina. The bank had $4 billion in assets, as of March 31. The company's trust and investment business holds assets under administration of around $7.7 billion. "Together, with over $36 billion in assets and over $82 billion in wealth assets under administration, we are poised to accelerate growth, expand our reach, and deliver even greater value,," said John Kemper, CEO of Kansas City, Missouri-based Commerce Bancshares. Keefe, Bruyette & Woods acted as financial adviser to Commerce Bancshares, while Piper Sandler advised FineMark. The transaction is expected to close on January 1.
